An accomplished drug developer and recognized leader in cell and gene therapy, Kevin brings more than twenty years of experience spanning scientific innovation, translational development, and executive leadership. Prior to founding Kelonia, he served as Vice President of Oncology Research and Development at bluebird bio, where he led the development of multiple programs including Abecma, the first approved anti-BCMA CAR T cell therapy for multiple myeloma. Kevin holds numerous patents and publications in the fields of immune-oncology and gene therapy. He earned his Ph.D. from Oregon Health & Science University and completed postdoctoral training in the Surgery Branch at the National Cancer Institute.

Travis Quigley is a seasoned leader in clinical development with more than 20 years of experience advancing innovative therapeutic programs. In his current role, he oversees the clinical and technical development operations teams, providing strategic direction to ensure operational excellence, cross-functional alignment, and efficient execution across the development lifecycle.

Previously, Travis has held senior leadership roles across the biotechnology and pharmaceutical sectors, including positions at K36 Therapeutics, Arcellx, bluebird bio, Foundation Medicine, and Infinity Pharmaceuticals. His experience spans early-stage development through late-phase clinical trials, with a strong focus on oncology and cell-based therapies.

Travis brings a patient-centered approach to drug development and is recognized for building and leading high-performing teams that deliver meaningful clinical impact.

Michael leads Kelonia’s legal strategy, intellectual property, and corporate governance functions, bringing deep expertise at the intersection of life sciences innovation and legal rigor.  Prior to joining Kelonia, he served as Chief IP Counsel at bluebird bio and was an associate/clerk in the Patent Life Sciences groups at Cooley LLP and Seed IP.  Michael earned his J.D. from Seattle University.  He also has deep scientific expertise, having earned a Ph.D. and M.S. in Cellular and Molecular Biology from Brandeis University as a graduate student in the lab of Nobel Laureate Dr. Michael Rosbash.  Michael’s multidisciplinary training and experience underpin Kelonia’s legal and IP framework as the company advances next-generation genetic medicines.

Stacy is Vice President of Talent & Culture at Kelonia Therapeutics, where she leads the company’s people strategy, organizational development, and culture initiatives to support the advancement of next-generation genetic medicines. She brings extensive experience building scalable talent, HR, and operational infrastructure for high-growth biotechnology companies, with prior leadership roles at Oncorus and bluebird bio, where she partnered closely with executive teams during periods of rapid growth and expansion.